Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FDJG2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,523
Award facts
- Contract value 100% obligated
- $19,522.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $19,522.72 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of ENTYVIO 300 MG vials. The delivery order, issued without set-aside designation, is scheduled for completion by December 10, 2025, and represents a routine procurement under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the agency. As a critical supplier within the Department of Defense pharmaceutical supply chain since 2001, DMS Pharmaceutical Group has demonstrated consistent performance across multiple therapeutic categories and product lines serving military healthcare facilities.
This delivery order operates under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion Defense Logistics Agency acquisition strategy that establishes multiple regional prime vendor contractors to support recurring pharmaceutical and medical supply needs across the DoD healthcare system. DMS Pharmaceutical Group's single-award Indefinite Delivery Contract under this program, valued at $499.99 million with a completion date of December 31, 2036, authorizes the company to supply branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables to military medical facilities worldwide. The current delivery order for ENTYVIO, a specialty biologic pharmaceutical, exemplifies the company's role in fulfilling the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FDJG2?
SPE2DR26FDJG2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 9, 2025.
How much is contract SPE2DR26FDJG2 worth?
The government has obligated $19,523 on SPE2DR26FDJG2.
Is contract SPE2DR26FDJG2 an order under another contract?
Yes. SPE2DR26FDJG2 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJG2 competed?
The extent of competition for SPE2DR26FDJG2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award